600351 亚宝药业
已收盘 11-16 15:00:00
资讯
新帖
简况
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于研发项目终止临床试验并计提减值准备的公告》
证券之星 · 11-16 02:10
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于研发项目终止临床试验并计提减值准备的公告》
亚宝药业(600351)披露研发项目终止临床试验并计提减值准备公告,11月13日股价下跌2.17%
证券之星 · 11-13
亚宝药业(600351)披露研发项目终止临床试验并计提减值准备公告,11月13日股价下跌2.17%
亚宝药业最新公告:终止SY-005注射液脓毒症项目临床并计提减值准备
证券之星 · 11-13
亚宝药业最新公告:终止SY-005注射液脓毒症项目临床并计提减值准备
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告》
证券之星 · 11-04
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告》
亚宝药业(600351)披露回购股份进展公告,11月2日股价下跌0.56%
证券之星 · 11-02
亚宝药业(600351)披露回购股份进展公告,11月2日股价下跌0.56%
亚宝药业:截至2026年10月20日,公司股东总户数为 47,913 户
证券之星 · 11-02
亚宝药业:截至2026年10月20日,公司股东总户数为 47,913 户
亚宝药业:公司董事长与总经理均为硕士研究生
证券之星 · 11-02
亚宝药业:公司董事长与总经理均为硕士研究生
亚宝药业(600351)10月30日主力资金净买入1245.40万元
证券之星 · 10-31
亚宝药业(600351)10月30日主力资金净买入1245.40万元
亚宝药业(600351)10月28日主力资金净买入6406.24万元
证券之星 · 10-29
亚宝药业(600351)10月28日主力资金净买入6406.24万元
异动快报:亚宝药业(600351)10月28日9点54分触及涨停板
证券之星 · 10-28
异动快报:亚宝药业(600351)10月28日9点54分触及涨停板
亚宝药业(600351)9月30日股东户数4.79万户,较上期增加0.9%
证券之星 · 10-27
亚宝药业(600351)9月30日股东户数4.79万户,较上期增加0.9%
亚宝药业(600351.SH)发布前三季度业绩,归母净利润2.57亿元,同比增长19.29%
智通财经 · 10-27
亚宝药业(600351.SH)发布前三季度业绩,归母净利润2.57亿元,同比增长19.29%
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于全资子公司以资本公积转增注册资本后减资进展暨完成工商变更登记的公告》
证券之星 · 10-21
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于全资子公司以资本公积转增注册资本后减资进展暨完成工商变更登记的公告》
亚宝药业(600351)披露全资子公司减资完成工商变更登记公告,10月19日股价上涨1.32%
证券之星 · 10-19
亚宝药业(600351)披露全资子公司减资完成工商变更登记公告,10月19日股价上涨1.32%
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告》
证券之星 · 10-12
股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告》
亚宝药业(600351)10月9日主力资金净买入2369.75万元
证券之星 · 10-10
亚宝药业(600351)10月9日主力资金净买入2369.75万元
亚宝药业(600351)9月30日股东户数4.79万户,较上期增加0.9%
证券之星 · 10-09
亚宝药业(600351)9月30日股东户数4.79万户,较上期增加0.9%
亚宝药业:公司积极关注并努力尝试AI技术在各个业务板块的运用
证券之星 · 10-09
亚宝药业:公司积极关注并努力尝试AI技术在各个业务板块的运用
亚宝药业:截止2026年9月20日,公司股东总户数为47,427户
证券之星 · 10-09
亚宝药业:截止2026年9月20日,公司股东总户数为47,427户
亚宝药业:公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定,在回购期限内根据市场情况择机做出回购决策并予以实施
证券之星 · 10-09
亚宝药业:公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定,在回购期限内根据市场情况择机做出回购决策并予以实施
加载更多
公司概况
公司名称:
亚宝药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2002-09-26
主营业务:
亚宝药业集团股份有限公司的主营业务是药品及大健康产品的研发、生产和销售。公司的主要产品是丁桂儿脐贴、薏芽健脾凝胶、儿童清咽解热口服液、甲钴胺片、盐酸倍他司汀注射液、红花注射液、硝苯地平缓释片、唯源素、唯源泰、唯源全。
发行价格:
4.80
{"stockData":{"symbol":"600351","market":"SH","secType":"STK","nameCN":"亚宝药业","latestPrice":6.48,"timestamp":1794812400000,"preClose":6.76,"halted":0,"volume":37453853,"delay":0,"changeRate":-0.0414,"floatShares":692000000,"shares":692000000,"eps":0.5225,"marketStatus":"已收盘","change":-0.28,"latestTime":"11-16 15:00:00","open":6.5,"high":6.55,"low":6.29,"amount":239000000,"amplitude":0.0385,"askPrice":6.49,"askSize":484,"bidPrice":6.48,"bidSize":261,"shortable":0,"etf":0,"ttmEps":0.5225,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794879000000},"marketStatusCode":5,"adr":0,"adjPreClose":6.76,"symbolType":"stock","openAndCloseTimeList":[[1794792600000,1794799800000],[1794805200000,1794812400000]],"highLimit":7.44,"lowLimit":6.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":692000046,"isCdr":false,"pbRate":1.63,"roa":"--","peRate":12.401914,"roe":"9.07%","epsLYR":0.46,"committee":-0.602463,"marketValue":4484000000,"turnoverRate":0.0541,"status":1,"floatMarketCap":4484000000},"requestUrl":"/m/hq/s/600351/","defaultTab":"news","newsList":[{"id":"2683573866","title":"股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于研发项目终止临床试验并计提减值准备的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683573866","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683573866?lang=zh_cn&edition=full","pubTime":"2026-11-16 02:10","pubTimestamp":1794766227,"startTime":"0","endTime":"0","summary":"公司公告汇总:亚宝药业终止SY-005注射液脓毒症适应症临床研究,全额计提减值准备6,983.87万元,减少2026年度利润总额同等金额。公司公告汇总亚宝药业集团股份有限公司关于研发项目终止临床试验并计提减值准备的公告亚宝药业集团股份有限公司决定终止SY-005注射液用于脓毒症适应症项目的临床研究开发工作,因该项目Ⅱ期临床未达到主要疗效终点,入组困难,研发周期长且投入大,获益与风险不匹配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600000734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0201","BK0077","BK0239","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683506729","title":"亚宝药业(600351)披露研发项目终止临床试验并计提减值准备公告,11月13日股价下跌2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683506729","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683506729?lang=zh_cn&edition=full","pubTime":"2026-11-13 22:14","pubTimestamp":1794579256,"startTime":"0","endTime":"0","summary":"截至2026年11月13日收盘,亚宝药业报收于6.76元,较前一交易日下跌2.17%,最新总市值为46.78亿元。该股当日开盘6.91元,最高6.92元,最低6.75元,成交额达1.51亿元,换手率为3.2%。近日,亚宝药业集团股份有限公司发布《关于研发项目终止临床试验并计提减值准备的公告》。公司将对该研发项目资本化金额6,983.87万元全额计提资产减值准备,减少2026年度利润总额6,983.87万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300043419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0028","BK0239","BK0077","BK0096","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683575364","title":"亚宝药业最新公告:终止SY-005注射液脓毒症项目临床并计提减值准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2683575364","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683575364?lang=zh_cn&edition=full","pubTime":"2026-11-13 16:59","pubTimestamp":1794560375,"startTime":"0","endTime":"0","summary":"亚宝药业(600351.SH)公告称,公司决定终止SY-005注射液用于脓毒症适应症项目的临床研究开发工作,并对该项目研发资本化金额6983.87万元全额计提资产减值准备,预计减少2026年度利润总额6983.87万元。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300030243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0201","BK0096","BK0239","BK0028","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680765547","title":"股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680765547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680765547?lang=zh_cn&edition=full","pubTime":"2026-11-04 01:37","pubTimestamp":1793727473,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘,亚宝药业报收于6.99元,下跌1.83%,换手率4.64%,成交量32.09万手,成交额2.25亿元。当日关注点交易信息汇总:11月3日主力资金净流出1403.19万元,占总成交额6.25%。公司公告汇总亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告截至2026年10月31日,公司已累计回购股份4,181,600股,占总股本的0.60%,支付总金额27,848,235.00元,回购价格区间为6.53元/股至6.74元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400002987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0028","BK0239","BK0077","BK0096","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680276317","title":"亚宝药业(600351)披露回购股份进展公告,11月2日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680276317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680276317?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:15","pubTimestamp":1793628941,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘,亚宝药业报收于7.12元,较前一交易日下跌0.56%,最新总市值为49.27亿元。该股当日开盘7.13元,最高7.23元,最低7.02元,成交额达2.57亿元,换手率为5.22%。近日,亚宝药业集团股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。截至2026年10月31日,公司已累计回购股份4,181,600股,占总股本的0.60%,支付总金额27,848,235.00元,回购价格区间为6.53元/股至6.74元/股。公司已实施的回购符合相关法规及回购方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200036694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","600351","BK0028","BK0096","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680739650","title":"亚宝药业:截至2026年10月20日,公司股东总户数为 47,913 户","url":"https://stock-news.laohu8.com/highlight/detail?id=2680739650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680739650?lang=zh_cn&edition=full","pubTime":"2026-11-02 15:33","pubTimestamp":1793604821,"startTime":"0","endTime":"0","summary":"证券之星消息,亚宝药业(600351)11月02日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司截止2026年10月20日的股东户数是多少?谢谢亚宝药业回复:投资者您好,截至2026年10月20日,公司股东总户数为 47,913 户。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200017470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","600351","BK0096","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680739500","title":"亚宝药业:公司董事长与总经理均为硕士研究生","url":"https://stock-news.laohu8.com/highlight/detail?id=2680739500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680739500?lang=zh_cn&edition=full","pubTime":"2026-11-02 15:33","pubTimestamp":1793604820,"startTime":"0","endTime":"0","summary":"证券之星消息,亚宝药业(600351)11月02日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,公司一直重视人才队伍建设,想了解下董事长任武贤、总经理任伟的毕业院校情况;另外公司是否有和该高校开展产学研、校企合作的布局?亚宝药业回复:投资者您好,公司董事长与总经理均为硕士研究生,感谢关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200017466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","600351","BK0096","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679260522","title":"亚宝药业(600351)10月30日主力资金净买入1245.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679260522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679260522?lang=zh_cn&edition=full","pubTime":"2026-10-31 08:23","pubTimestamp":1793406187,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月30日收盘,亚宝药业报收于7.16元,上涨0.85%,换手率5.51%,成交量38.12万手,成交额2.72亿元。近5日资金流向一览见下表:亚宝药业融资融券信息显示,融资方面,当日融资买入2427.07万元,融资偿还1961.56万元,融资净买入465.5万元。亚宝药业主营业务:公司主要从事药品的研发、生产和销售,现有产品涵盖中西药制剂、贴敷剂、原料药和药用包装材料等共计300多个品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100018289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0028","600351","BK0096","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679446370","title":"亚宝药业(600351)10月28日主力资金净买入6406.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679446370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679446370?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:23","pubTimestamp":1793233416,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月28日收盘,亚宝药业报收于7.15元,上涨7.84%,换手率11.71%,成交量81.06万手,成交额5.81亿元。近5日资金流向一览见下表:亚宝药业融资融券信息显示,融资方面,当日融资买入4870.59万元,融资偿还3948.88万元,融资净买入921.72万元。亚宝药业主营业务:公司主要从事药品的研发、生产和销售,现有产品涵盖中西药制剂、贴敷剂、原料药和药用包装材料等共计300多个品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900012650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0077","BK0028","BK0096","BK0239","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678743302","title":"异动快报:亚宝药业(600351)10月28日9点54分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2678743302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678743302?lang=zh_cn&edition=full","pubTime":"2026-10-28 09:55","pubTimestamp":1793152527,"startTime":"0","endTime":"0","summary":"证券之星10月28日盘中消息,9点54分亚宝药业(600351)触及涨停板。其所属行业中药目前上涨。领涨股为亚宝药业。该股为创新药,优化生育(三孩),医药概念热股,当日创新药概念上涨1.11%,优化生育(三孩)概念上涨0.91%,医药概念上涨0.83%。10月27日的资金流向数据方面,主力资金净流出358.44万元,占总成交额3.2%,游资资金净流入670.01万元,占总成交额5.98%,散户资金净流出311.58万元,占总成交额2.78%。近5日资金流向一览见下表:亚宝药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800017293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","600351","BK0201","BK0077","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678173913","title":"亚宝药业(600351)9月30日股东户数4.79万户,较上期增加0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678173913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678173913?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:31","pubTimestamp":1793097097,"startTime":"0","endTime":"0","summary":"证券之星消息,近日亚宝药业披露,截至2026年9月30日公司股东户数为4.79万户,较9月20日增加426.0户,增幅为0.9%。在中药行业个股中,亚宝药业股东户数低于行业平均水平,截至9月30日,中药行业平均股东户数为5.24万户。从股价来看,2026年9月20日至2026年9月30日,亚宝药业区间涨幅为3.18%,在此期间股东户数增加426.0户,增幅为0.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700034132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0201","BK0239","BK0077","BK0096","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678122465","title":"亚宝药业(600351.SH)发布前三季度业绩,归母净利润2.57亿元,同比增长19.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678122465","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678122465?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:16","pubTimestamp":1793092605,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚宝药业(600351.SH)披露2026年第三季度报告,前三季度公司实现业收入16.63亿元,同比下降2.67%;归母净利润2.57亿元,同比增长19.29%;扣非净利润2.58亿元,同比增长30.47%;基本每股收益0.3708元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677133966","title":"股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于全资子公司以资本公积转增注册资本后减资进展暨完成工商变更登记的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677133966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677133966?lang=zh_cn&edition=full","pubTime":"2026-10-21 02:04","pubTimestamp":1792519453,"startTime":"0","endTime":"0","summary":"公司公告汇总亚宝药业集团股份有限公司关于全资子公司以资本公积转增注册资本后减资进展暨完成工商变更登记的公告亚宝北中大(北京)制药有限公司于2026年7月31日经董事会审议通过,以3,730.34万元资本公积转增注册资本,注册资本由5,600万元增至9,330.34万元;随后减资9,130.34万元,注册资本变更为200万元。亚宝药业仍持有其100%股权。亚宝药业持股比例保持80%不变。2026年10月19日已完成工商变更登记并取得新《营业执照》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","600351","BK0096","BK0239","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676684914","title":"亚宝药业(600351)披露全资子公司减资完成工商变更登记公告,10月19日股价上涨1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676684914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676684914?lang=zh_cn&edition=full","pubTime":"2026-10-19 22:33","pubTimestamp":1792420427,"startTime":"0","endTime":"0","summary":"近日,亚宝药业集团股份有限公司发布《关于全资子公司以资本公积转增注册资本后减资进展暨完成工商变更登记的公告》。公告显示,公司于2026年7月31日召开第十届董事会第二次会议,审议通过子公司亚宝北中大(北京)制药有限公司以3,730.34万元资本公积转增注册资本,注册资本由5,600万元增至9,330.34万元。增资完成后,亚宝北中大减资9,130.34万元,注册资本变更为200万元。公司仍持有亚宝北中大100%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900030366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0096","BK0239","BK0028","600351","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674406843","title":"股市必读:亚宝药业新发布《亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674406843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674406843?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:17","pubTimestamp":1791739027,"startTime":"0","endTime":"0","summary":"公司公告汇总亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告亚宝药业于2026年8月18日召开2026年第三次临时股东会,审议通过回购股份方案,拟以集中竞价交易方式回购股份,资金总额不低于1亿元且不超过2亿元,回购价格不超过6.75元/股,回购期限为2026年8月18日至2027年8月17日,回购股份用于减少注册资本;截至2026年9月30日,已累计回购748,900股,占公司总股本的0.11%,支付金额4,999,373.00元,成交价区间为6.58元/股至6.74元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0096","BK0201","BK0077","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674986705","title":"亚宝药业(600351)10月9日主力资金净买入2369.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674986705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674986705?lang=zh_cn&edition=full","pubTime":"2026-10-10 08:17","pubTimestamp":1791591472,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月9日收盘,亚宝药业报收于7.07元,上涨3.67%,换手率5.67%,成交量39.22万手,成交额2.74亿元。近5日资金流向一览见下表:亚宝药业融资融券信息显示,融资方面,当日融资买入1762.18万元,融资偿还2161.1万元,融资净偿还398.92万元。亚宝药业主营业务:公司主要从事药品的研发、生产和销售,现有产品涵盖中西药制剂、贴敷剂、原料药和药用包装材料等共计300多个品种。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101000003869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0028","BK0239","BK0077","BK0096","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674914830","title":"亚宝药业(600351)9月30日股东户数4.79万户,较上期增加0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674914830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674914830?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:30","pubTimestamp":1791538256,"startTime":"0","endTime":"0","summary":"证券之星消息,近日亚宝药业披露,截至2026年9月30日公司股东户数为4.79万户,较9月20日增加426.0户,增幅为0.9%。在中药行业个股中,亚宝药业股东户数低于行业平均水平,截至9月30日,中药行业平均股东户数为5.22万户。从股价来看,2026年9月20日至2026年9月30日,亚宝药业区间涨幅为3.18%,在此期间股东户数增加426.0户,增幅为0.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900027159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0028","BK0239","BK0077","BK0096","600351"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831598","title":"亚宝药业:公司积极关注并努力尝试AI技术在各个业务板块的运用","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674831598?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:33","pubTimestamp":1791531221,"startTime":"0","endTime":"0","summary":"证券之星消息,亚宝药业(600351)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问:目前AI在创新药领域发展迅猛,公司有没有计划在创新方面引入AI技术?亚宝药业回复:投资者您好,公司积极关注并努力尝试AI技术在各个业务板块的运用。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900018901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0028","BK0096","BK0077","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674183137","title":"亚宝药业:截止2026年9月20日,公司股东总户数为47,427户","url":"https://stock-news.laohu8.com/highlight/detail?id=2674183137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674183137?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:33","pubTimestamp":1791531207,"startTime":"0","endTime":"0","summary":"证券之星消息,亚宝药业(600351)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止至2026年9月20日公司股东人数是多少亚宝药业回复:投资者您好,截止2026年9月20日,公司股东总户数为47,427户。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900018888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0096","BK0201","BK0077","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831551","title":"亚宝药业:公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定,在回购期限内根据市场情况择机做出回购决策并予以实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674831551?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:33","pubTimestamp":1791531204,"startTime":"0","endTime":"0","summary":"证券之星消息,亚宝药业(600351)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问:公司目前回购价上限为6.75元,如果后续股价高于上限导致回购不能按时完成,,公司是否会考虑提高回购价上限以完成计划?亚宝药业回复:投资者您好,公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定,在回购期限内根据市场情况择机做出回购决策并予以实施。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900018885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600351","BK0077","BK0201","BK0096","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794852425048,"stockEarnings":[{"period":"1week","weight":-0.0609},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0596},{"period":"6month","weight":0.0525},{"period":"1year","weight":-0.0006},{"period":"ytd","weight":0.084}],"compareEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0306},{"period":"3month","weight":-0.0972},{"period":"6month","weight":-0.1345},{"period":"1year","weight":-0.0972},{"period":"ytd","weight":-0.0923}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"亚宝药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48760人(较上一季度减少0.95%)","perCapita":"14191股","listingDate":"2002-09-26","address":"山西省运城市芮城县富民路43号","registeredCapital":"69200万元","survey":" 亚宝药业集团股份有限公司的主营业务是药品及大健康产品的研发、生产和销售。公司的主要产品是丁桂儿脐贴、薏芽健脾凝胶、儿童清咽解热口服液、甲钴胺片、盐酸倍他司汀注射液、红花注射液、硝苯地平缓释片、唯源素、唯源泰、唯源全。","listedPrice":4.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚宝药业(600351)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚宝药业(600351)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚宝药业,600351,亚宝药业股票,亚宝药业股票老虎,亚宝药业股票老虎国际,亚宝药业行情,亚宝药业股票行情,亚宝药业股价,亚宝药业股市,亚宝药业股票价格,亚宝药业股票交易,亚宝药业股票购买,亚宝药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚宝药业(600351)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚宝药业(600351)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}